Trial Profile

A phase I study assessing SLN360 in cardiovascular disorders

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 24 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zerlasiran (Primary)
Indications Cardiovascular disorders
Focus Adverse reactions; First in man

Most Recent Events

20 May 2020 According to a Silence Therapeutics media release, in spite of the COVID-19 pandemic, the company still expects to start this trial this year.
25 Mar 2020 According to a Silence Therapeutics media release, the company expects to generate interim data from the trial around the middle of 2021.
10 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com